Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because you know what we are going to say — the usual routine of meetings, deadlines, and the like has returned with a vengeance. The only way to cope is to fire up the coffee kettle and brew some cups of stimulation. As always, please feel free to join us. We prefer not to drink alone. Meanwhile, here are some tidbits. Have a lovely day and do keep in touch …
Alexion Pharmaceuticals has finally hired a new chief executive, tapping Ludwig Hantson, who was most recently running Baxalta. The move comes after an extraordinary episode that began in November, when an unnamed employee charged the drug maker engaged in fraud to hawk its biggest medicine. Since then, the company installed an interim executive team and more recently disclosed that senior management pressured employees to convince customers to order the drug to meet financial targets.
The Korean Ministry of Health and Welfare may suspend insurance benefits to some Novartis products as a result of a bribery scandal in which doctors were paid to prescribe medicines, KoreaBiomed writes. The suspension would follow a $177,000 fine and suspended sales of 12 drugs for three months that was recently imposed by the Ministry of Food and Drug Safety.
About the Author Reprints
